239 related articles for article (PubMed ID: 37195586)
1. Urothelial Bladder Cancer: Genomic Alterations in Fibroblast Growth Factor Receptor.
Bou Zerdan M; Bratslavsky G; Jacob J; Ross J; Huang R; Basnet A
Mol Diagn Ther; 2023 Jul; 27(4):475-485. PubMed ID: 37195586
[TBL] [Abstract][Full Text] [Related]
2. Pan-tumor landscape of fibroblast growth factor receptor 1-4 genomic alterations.
Murugesan K; Necchi A; Burn TC; Gjoerup O; Greenstein R; Krook M; López JA; Montesion M; Nimeiri H; Parikh AR; Roychowdhury S; Schwemmers S; Silverman IM; Vogel A
ESMO Open; 2022 Dec; 7(6):100641. PubMed ID: 36462464
[TBL] [Abstract][Full Text] [Related]
3. HPV-positive clinically advanced squamous cell carcinoma of the urinary bladder (aBSCC): A comprehensive genomic profiling (CGP) study.
Ghelani GH; Zerdan MB; Jacob J; Spiess PE; Li R; Necchi A; Grivas P; Kamat A; Danziger N; Lin D; Huang R; Decker B; Sokol ES; Cheng L; Pavlick D; Ross JS; Bratslavsky G; Basnet A
Urol Oncol; 2023 Dec; 41(12):486.e15-486.e23. PubMed ID: 37821306
[TBL] [Abstract][Full Text] [Related]
4. Frequency and Nature of Genomic Alterations in ERBB2-Altered Urothelial Bladder Cancer.
Leary JB; Enright T; Bakaloudi DR; Basnet A; Bratslavsky G; Jacob J; Spiess PE; Li R; Necchi A; Kamat AM; Pavlick DC; Danziger N; Huang RSP; Lin DI; Cheng L; Ross J; Talukder R; Grivas P
Target Oncol; 2024 May; 19(3):447-458. PubMed ID: 38570422
[TBL] [Abstract][Full Text] [Related]
5. Fibroblast Growth Factor Inhibitors for Treating Locally Advanced/Metastatic Bladder Urothelial Carcinomas via Dual Targeting of Tumor-Specific Oncogenic Signaling and the Tumor Immune Microenvironment.
Lee HW; Seo HK
Int J Mol Sci; 2021 Sep; 22(17):. PubMed ID: 34502435
[TBL] [Abstract][Full Text] [Related]
6. Novel synthetic lethality drug target in urothelial bladder cancer based on MTAP genomic loss.
Basin MF; Bratslavsky G; Nahhas N; Basnet A; Goldberg H; Necchi A; Sokol ES; Ramkissoon SH; Huang RSP; Ross JS; Jacob JM
Urol Oncol; 2023 Feb; 41(2):109.e15-109.e22. PubMed ID: 36443178
[TBL] [Abstract][Full Text] [Related]
7. Recurrent urothelial carcinoma-like FGFR3 genomic alterations in malignant Brenner tumors of the ovary.
Lin DI; Killian JK; Venstrom JM; Ramkissoon SH; Ross JS; Elvin JA
Mod Pathol; 2021 May; 34(5):983-993. PubMed ID: 33077920
[TBL] [Abstract][Full Text] [Related]
8. Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience.
Rose TL; Weir WH; Mayhew GM; Shibata Y; Eulitt P; Uronis JM; Zhou M; Nielsen M; Smith AB; Woods M; Hayward MC; Salazar AH; Milowsky MI; Wobker SE; McGinty K; Millburn MV; Eisner JR; Kim WY
Br J Cancer; 2021 Oct; 125(9):1251-1260. PubMed ID: 34294892
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive Landscape of Cyclin Pathway Gene Alterations and Co-occurrence with FGF/FGFR Aberrations Across Urinary Tract Tumors.
Jardim DLF; Millis SZ; Ross JS; Lippman S; Ali SM; Kurzrock R
Oncologist; 2023 Feb; 28(2):e82-e91. PubMed ID: 36082904
[TBL] [Abstract][Full Text] [Related]
10. Detection of Known and Novel FGFR Fusions in Non-Small Cell Lung Cancer by Comprehensive Genomic Profiling.
Qin A; Johnson A; Ross JS; Miller VA; Ali SM; Schrock AB; Gadgeel SM
J Thorac Oncol; 2019 Jan; 14(1):54-62. PubMed ID: 30267839
[TBL] [Abstract][Full Text] [Related]
11. Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer.
Weickhardt AJ; Lau DK; Hodgson-Garms M; Lavis A; Jenkins LJ; Vukelic N; Ioannidis P; Luk IY; Mariadason JM
BMC Cancer; 2022 May; 22(1):478. PubMed ID: 35501832
[TBL] [Abstract][Full Text] [Related]
12. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
Manzano RG; Catalan-Latorre A; Brugarolas A
BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
[TBL] [Abstract][Full Text] [Related]
13. FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review).
Katoh M
Int J Mol Med; 2016 Jul; 38(1):3-15. PubMed ID: 27245147
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Role of FGFR Alterations and FGFR mRNA Expression in Metastatic Urothelial Cancer Undergoing Checkpoint Inhibitor Therapy.
Tully KH; Jütte H; Wirtz RM; Jarczyk J; Santiago-Walker A; Zengerling F; Breyer J; Sikic D; Kriegmair MC; von Hardenberg J; Wullich B; Taubert H; Weyerer V; Stoehr R; Bolenz C; Burger M; Porubsky S; Hartmann A; Roghmann F; Erben P; Eckstein M
Urology; 2021 Nov; 157():93-101. PubMed ID: 34153367
[TBL] [Abstract][Full Text] [Related]
15. Fibroblast growth factor receptor 3 mutation attenuates response to immune checkpoint blockade in metastatic urothelial carcinoma by driving immunosuppressive microenvironment.
Song Y; Peng Y; Qin C; Wang Y; Yang W; Du Y; Xu T
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37777251
[TBL] [Abstract][Full Text] [Related]
16. Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience.
Guercio BJ; Sarfaty M; Teo MY; Ratna N; Duzgol C; Funt SA; Lee CH; Aggen DH; Regazzi AM; Chen Z; Lattanzi M; Al-Ahmadie HA; Brannon AR; Shah R; Chu C; Lenis AT; Pietzak E; Bochner BH; Berger MF; Solit DB; Rosenberg JE; Bajorin DF; Iyer G
Clin Cancer Res; 2023 Nov; 29(22):4586-4595. PubMed ID: 37682528
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic and Genomic Characterization of PD-L1 Positive Urothelial Carcinomas.
Huang RSP; Haberberger J; Harries L; Severson E; Duncan DL; Ferguson NL; Hemmerich A; Edgerly C; Murugesan K; Xiao J; McEwan D; Holmes O; Hiemenz M; Venstrom J; Elvin JA; Creeden J; Lin DI; Ross JS; Ramkissoon SH
Oncologist; 2021 May; 26(5):375-382. PubMed ID: 33687775
[TBL] [Abstract][Full Text] [Related]
18. Urothelial carcinoma: the development of FGFR inhibitors in combination with immune checkpoint inhibitors.
Qin Q; Patel V; Galsky MD
Expert Rev Anticancer Ther; 2020 Jun; 20(6):503-512. PubMed ID: 32436413
[TBL] [Abstract][Full Text] [Related]
19. Can Patients with Muscle-invasive Bladder Cancer and Fibroblast Growth Factor Receptor-3 Alterations Still Be Considered for Neoadjuvant Pembrolizumab? A Comprehensive Assessment from the Updated Results of the PURE-01 Study.
Necchi A; Raggi D; Giannatempo P; Marandino L; Farè E; Gallina A; Colecchia M; Lucianò R; Salonia A; Gandaglia G; Fossati N; Bandini M; Pederzoli F; Dittamore R; Liu Y; Davicioni E; Ross JS; de Jong JJ; Briganti A; Montorsi F; Gibb EA
Eur Urol Oncol; 2021 Dec; 4(6):1001-1005. PubMed ID: 32417369
[TBL] [Abstract][Full Text] [Related]
20. Role of FGFR3 in bladder cancer: Treatment landscape and future challenges.
Ascione CM; Napolitano F; Esposito D; Servetto A; Belli S; Santaniello A; Scagliarini S; Crocetto F; Bianco R; Formisano L
Cancer Treat Rev; 2023 Apr; 115():102530. PubMed ID: 36898352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]